Loading…

Seizures Triggered by Systemic Administration of 4-Aminopyridine in Rats Lead to Acute Brain Glucose Hypometabolism, as Assessed by [ 18 F]FDG PET Neuroimaging

4-aminopyridine (4-AP) is a non-selective blocker of voltage-dependent K channels used to improve walking in multiple sclerosis patients, and it may be useful in the treatment of cerebellar diseases. In animal models, 4-AP is used as a convulsant agent. When administered intrahippocampally, 4-AP ind...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-12, Vol.25 (23), p.12774
Main Authors: Gómez-Oliver, Francisca, Fernández de la Rosa, Rubén, Brackhan, Mirjam, Bascuñana, Pablo, Pozo, Miguel Ángel, García-García, Luis
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 23
container_start_page 12774
container_title International journal of molecular sciences
container_volume 25
creator Gómez-Oliver, Francisca
Fernández de la Rosa, Rubén
Brackhan, Mirjam
Bascuñana, Pablo
Pozo, Miguel Ángel
García-García, Luis
description 4-aminopyridine (4-AP) is a non-selective blocker of voltage-dependent K channels used to improve walking in multiple sclerosis patients, and it may be useful in the treatment of cerebellar diseases. In animal models, 4-AP is used as a convulsant agent. When administered intrahippocampally, 4-AP induces acute local glucose hypermetabolism and significant brain damage, while i.p. administration causes less neuronal damage. This study aimed to investigate the effects of a single i.p. administration of 4-AP on acute brain glucose metabolism as well as on neuronal viability and signs of neuroinflammation 3 days after the insult. Brain glucose metabolism was evaluated by [ F]FDG PET neuroimaging. [ F]FDG uptake was analyzed based on volumes of interest (VOIs) as well as by voxel-based (SPM) analyses. The results showed that independently of the type of data analysis used (VOIs or SPM), 4-AP induced acute generalized brain glucose hypometabolism, except in the cerebellum. Furthermore, the SPM analysis normalized by the whole brain uptake revealed a significant cerebellar hypermetabolism. The neurohistochemical assays showed that 4-AP induced hippocampal astrocyte reactivity 3 days after the insult, without inducing changes in neuronal integrity or microglia-mediated neuroinflammation. Thus, acute brain glucose metabolic and neuroinflammatory profiles in response to i.p. 4-AP clearly differed from that reported for intrahippocampal administration. Finally, the results suggest that the cerebellum might be more resilient to the 4-AP-induced hypometabolism.
doi_str_mv 10.3390/ijms252312774
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_3144194489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3144194489</sourcerecordid><originalsourceid>FETCH-LOGICAL-p515-d8d5a049218604760a3f3c1c5b3367e8e5df0b5da8e116fb04ee73b50d14c02f3</originalsourceid><addsrcrecordid>eNo1UE1L5EAUbMTFUdejV3ng1bj9neQYR2dcGHZF57bI0Em_DD1M0rE7OcQ_41816Cw8qEdV8epRhFwyeitETn-5XRO54oLxNJVH5JRJzhNKdXo87VqzRKtcz8hZjDtKueAqPyEzketMykydko8XdO9DwAjr4LZbDGihHOFljD02roLCNq51sQ-md74FX4NMiony3RicdS2Ca-HZ9BFWaCz0Hopq6BHugpmE5X6ofER4HDvfYG9Kv3exuQEToYgRp_lK-wcsg8Xr4n4JTw9r-IND8K4xW9duf5IftdlHvDjgOVkvHtbzx2T1d_l7XqySTjGV2MwqQ2XOWaapTDU1ohYVq1QphE4xQ2VrWiprMmRM1yWViKkoFbVMVpTX4pxcf5_tgn8bMPabnR9COyVuBJOS5VNb-eS6OriGskG76cL0ZRg3_-sUn-eud2c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3144194489</pqid></control><display><type>article</type><title>Seizures Triggered by Systemic Administration of 4-Aminopyridine in Rats Lead to Acute Brain Glucose Hypometabolism, as Assessed by [ 18 F]FDG PET Neuroimaging</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Gómez-Oliver, Francisca ; Fernández de la Rosa, Rubén ; Brackhan, Mirjam ; Bascuñana, Pablo ; Pozo, Miguel Ángel ; García-García, Luis</creator><creatorcontrib>Gómez-Oliver, Francisca ; Fernández de la Rosa, Rubén ; Brackhan, Mirjam ; Bascuñana, Pablo ; Pozo, Miguel Ángel ; García-García, Luis</creatorcontrib><description>4-aminopyridine (4-AP) is a non-selective blocker of voltage-dependent K channels used to improve walking in multiple sclerosis patients, and it may be useful in the treatment of cerebellar diseases. In animal models, 4-AP is used as a convulsant agent. When administered intrahippocampally, 4-AP induces acute local glucose hypermetabolism and significant brain damage, while i.p. administration causes less neuronal damage. This study aimed to investigate the effects of a single i.p. administration of 4-AP on acute brain glucose metabolism as well as on neuronal viability and signs of neuroinflammation 3 days after the insult. Brain glucose metabolism was evaluated by [ F]FDG PET neuroimaging. [ F]FDG uptake was analyzed based on volumes of interest (VOIs) as well as by voxel-based (SPM) analyses. The results showed that independently of the type of data analysis used (VOIs or SPM), 4-AP induced acute generalized brain glucose hypometabolism, except in the cerebellum. Furthermore, the SPM analysis normalized by the whole brain uptake revealed a significant cerebellar hypermetabolism. The neurohistochemical assays showed that 4-AP induced hippocampal astrocyte reactivity 3 days after the insult, without inducing changes in neuronal integrity or microglia-mediated neuroinflammation. Thus, acute brain glucose metabolic and neuroinflammatory profiles in response to i.p. 4-AP clearly differed from that reported for intrahippocampal administration. Finally, the results suggest that the cerebellum might be more resilient to the 4-AP-induced hypometabolism.</description><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms252312774</identifier><identifier>PMID: 39684485</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>4-Aminopyridine - pharmacology ; Animals ; Brain - diagnostic imaging ; Brain - drug effects ; Brain - metabolism ; Brain - pathology ; Brain damage ; Convulsions &amp; seizures ; Epilepsy ; Fluorodeoxyglucose F18 ; Glucose ; Glucose - metabolism ; Male ; Medical imaging ; Metabolism ; Multiple sclerosis ; Musculoskeletal system ; Neurodegeneration ; Neuroimaging ; Neuroimaging - methods ; Positron-Emission Tomography - methods ; Rats ; Rats, Wistar ; Seizures - chemically induced ; Seizures - diagnostic imaging ; Seizures - drug therapy ; Seizures - metabolism</subject><ispartof>International journal of molecular sciences, 2024-12, Vol.25 (23), p.12774</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-9303-0513 ; 0000-0002-5704-5387 ; 0000-0001-5896-3107 ; 0000-0003-2186-8899</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3144194489/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3144194489?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39684485$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez-Oliver, Francisca</creatorcontrib><creatorcontrib>Fernández de la Rosa, Rubén</creatorcontrib><creatorcontrib>Brackhan, Mirjam</creatorcontrib><creatorcontrib>Bascuñana, Pablo</creatorcontrib><creatorcontrib>Pozo, Miguel Ángel</creatorcontrib><creatorcontrib>García-García, Luis</creatorcontrib><title>Seizures Triggered by Systemic Administration of 4-Aminopyridine in Rats Lead to Acute Brain Glucose Hypometabolism, as Assessed by [ 18 F]FDG PET Neuroimaging</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>4-aminopyridine (4-AP) is a non-selective blocker of voltage-dependent K channels used to improve walking in multiple sclerosis patients, and it may be useful in the treatment of cerebellar diseases. In animal models, 4-AP is used as a convulsant agent. When administered intrahippocampally, 4-AP induces acute local glucose hypermetabolism and significant brain damage, while i.p. administration causes less neuronal damage. This study aimed to investigate the effects of a single i.p. administration of 4-AP on acute brain glucose metabolism as well as on neuronal viability and signs of neuroinflammation 3 days after the insult. Brain glucose metabolism was evaluated by [ F]FDG PET neuroimaging. [ F]FDG uptake was analyzed based on volumes of interest (VOIs) as well as by voxel-based (SPM) analyses. The results showed that independently of the type of data analysis used (VOIs or SPM), 4-AP induced acute generalized brain glucose hypometabolism, except in the cerebellum. Furthermore, the SPM analysis normalized by the whole brain uptake revealed a significant cerebellar hypermetabolism. The neurohistochemical assays showed that 4-AP induced hippocampal astrocyte reactivity 3 days after the insult, without inducing changes in neuronal integrity or microglia-mediated neuroinflammation. Thus, acute brain glucose metabolic and neuroinflammatory profiles in response to i.p. 4-AP clearly differed from that reported for intrahippocampal administration. Finally, the results suggest that the cerebellum might be more resilient to the 4-AP-induced hypometabolism.</description><subject>4-Aminopyridine - pharmacology</subject><subject>Animals</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Brain - pathology</subject><subject>Brain damage</subject><subject>Convulsions &amp; seizures</subject><subject>Epilepsy</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glucose</subject><subject>Glucose - metabolism</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Metabolism</subject><subject>Multiple sclerosis</subject><subject>Musculoskeletal system</subject><subject>Neurodegeneration</subject><subject>Neuroimaging</subject><subject>Neuroimaging - methods</subject><subject>Positron-Emission Tomography - methods</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Seizures - chemically induced</subject><subject>Seizures - diagnostic imaging</subject><subject>Seizures - drug therapy</subject><subject>Seizures - metabolism</subject><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNo1UE1L5EAUbMTFUdejV3ng1bj9neQYR2dcGHZF57bI0Em_DD1M0rE7OcQ_41816Cw8qEdV8epRhFwyeitETn-5XRO54oLxNJVH5JRJzhNKdXo87VqzRKtcz8hZjDtKueAqPyEzketMykydko8XdO9DwAjr4LZbDGihHOFljD02roLCNq51sQ-md74FX4NMiony3RicdS2Ca-HZ9BFWaCz0Hopq6BHugpmE5X6ofER4HDvfYG9Kv3exuQEToYgRp_lK-wcsg8Xr4n4JTw9r-IND8K4xW9duf5IftdlHvDjgOVkvHtbzx2T1d_l7XqySTjGV2MwqQ2XOWaapTDU1ohYVq1QphE4xQ2VrWiprMmRM1yWViKkoFbVMVpTX4pxcf5_tgn8bMPabnR9COyVuBJOS5VNb-eS6OriGskG76cL0ZRg3_-sUn-eud2c</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Gómez-Oliver, Francisca</creator><creator>Fernández de la Rosa, Rubén</creator><creator>Brackhan, Mirjam</creator><creator>Bascuñana, Pablo</creator><creator>Pozo, Miguel Ángel</creator><creator>García-García, Luis</creator><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><orcidid>https://orcid.org/0000-0001-9303-0513</orcidid><orcidid>https://orcid.org/0000-0002-5704-5387</orcidid><orcidid>https://orcid.org/0000-0001-5896-3107</orcidid><orcidid>https://orcid.org/0000-0003-2186-8899</orcidid></search><sort><creationdate>20241201</creationdate><title>Seizures Triggered by Systemic Administration of 4-Aminopyridine in Rats Lead to Acute Brain Glucose Hypometabolism, as Assessed by [ 18 F]FDG PET Neuroimaging</title><author>Gómez-Oliver, Francisca ; Fernández de la Rosa, Rubén ; Brackhan, Mirjam ; Bascuñana, Pablo ; Pozo, Miguel Ángel ; García-García, Luis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p515-d8d5a049218604760a3f3c1c5b3367e8e5df0b5da8e116fb04ee73b50d14c02f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>4-Aminopyridine - pharmacology</topic><topic>Animals</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Brain - pathology</topic><topic>Brain damage</topic><topic>Convulsions &amp; seizures</topic><topic>Epilepsy</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glucose</topic><topic>Glucose - metabolism</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Metabolism</topic><topic>Multiple sclerosis</topic><topic>Musculoskeletal system</topic><topic>Neurodegeneration</topic><topic>Neuroimaging</topic><topic>Neuroimaging - methods</topic><topic>Positron-Emission Tomography - methods</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Seizures - chemically induced</topic><topic>Seizures - diagnostic imaging</topic><topic>Seizures - drug therapy</topic><topic>Seizures - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez-Oliver, Francisca</creatorcontrib><creatorcontrib>Fernández de la Rosa, Rubén</creatorcontrib><creatorcontrib>Brackhan, Mirjam</creatorcontrib><creatorcontrib>Bascuñana, Pablo</creatorcontrib><creatorcontrib>Pozo, Miguel Ángel</creatorcontrib><creatorcontrib>García-García, Luis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Health &amp; Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez-Oliver, Francisca</au><au>Fernández de la Rosa, Rubén</au><au>Brackhan, Mirjam</au><au>Bascuñana, Pablo</au><au>Pozo, Miguel Ángel</au><au>García-García, Luis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Seizures Triggered by Systemic Administration of 4-Aminopyridine in Rats Lead to Acute Brain Glucose Hypometabolism, as Assessed by [ 18 F]FDG PET Neuroimaging</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>25</volume><issue>23</issue><spage>12774</spage><pages>12774-</pages><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>4-aminopyridine (4-AP) is a non-selective blocker of voltage-dependent K channels used to improve walking in multiple sclerosis patients, and it may be useful in the treatment of cerebellar diseases. In animal models, 4-AP is used as a convulsant agent. When administered intrahippocampally, 4-AP induces acute local glucose hypermetabolism and significant brain damage, while i.p. administration causes less neuronal damage. This study aimed to investigate the effects of a single i.p. administration of 4-AP on acute brain glucose metabolism as well as on neuronal viability and signs of neuroinflammation 3 days after the insult. Brain glucose metabolism was evaluated by [ F]FDG PET neuroimaging. [ F]FDG uptake was analyzed based on volumes of interest (VOIs) as well as by voxel-based (SPM) analyses. The results showed that independently of the type of data analysis used (VOIs or SPM), 4-AP induced acute generalized brain glucose hypometabolism, except in the cerebellum. Furthermore, the SPM analysis normalized by the whole brain uptake revealed a significant cerebellar hypermetabolism. The neurohistochemical assays showed that 4-AP induced hippocampal astrocyte reactivity 3 days after the insult, without inducing changes in neuronal integrity or microglia-mediated neuroinflammation. Thus, acute brain glucose metabolic and neuroinflammatory profiles in response to i.p. 4-AP clearly differed from that reported for intrahippocampal administration. Finally, the results suggest that the cerebellum might be more resilient to the 4-AP-induced hypometabolism.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39684485</pmid><doi>10.3390/ijms252312774</doi><orcidid>https://orcid.org/0000-0001-9303-0513</orcidid><orcidid>https://orcid.org/0000-0002-5704-5387</orcidid><orcidid>https://orcid.org/0000-0001-5896-3107</orcidid><orcidid>https://orcid.org/0000-0003-2186-8899</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1661-6596
ispartof International journal of molecular sciences, 2024-12, Vol.25 (23), p.12774
issn 1661-6596
1422-0067
language eng
recordid cdi_proquest_journals_3144194489
source Open Access: PubMed Central; Publicly Available Content Database
subjects 4-Aminopyridine - pharmacology
Animals
Brain - diagnostic imaging
Brain - drug effects
Brain - metabolism
Brain - pathology
Brain damage
Convulsions & seizures
Epilepsy
Fluorodeoxyglucose F18
Glucose
Glucose - metabolism
Male
Medical imaging
Metabolism
Multiple sclerosis
Musculoskeletal system
Neurodegeneration
Neuroimaging
Neuroimaging - methods
Positron-Emission Tomography - methods
Rats
Rats, Wistar
Seizures - chemically induced
Seizures - diagnostic imaging
Seizures - drug therapy
Seizures - metabolism
title Seizures Triggered by Systemic Administration of 4-Aminopyridine in Rats Lead to Acute Brain Glucose Hypometabolism, as Assessed by [ 18 F]FDG PET Neuroimaging
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A16%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Seizures%20Triggered%20by%20Systemic%20Administration%20of%204-Aminopyridine%20in%20Rats%20Lead%20to%20Acute%20Brain%20Glucose%20Hypometabolism,%20as%20Assessed%20by%20%5B%2018%20F%5DFDG%20PET%20Neuroimaging&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=G%C3%B3mez-Oliver,%20Francisca&rft.date=2024-12-01&rft.volume=25&rft.issue=23&rft.spage=12774&rft.pages=12774-&rft.issn=1661-6596&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms252312774&rft_dat=%3Cproquest_pubme%3E3144194489%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p515-d8d5a049218604760a3f3c1c5b3367e8e5df0b5da8e116fb04ee73b50d14c02f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3144194489&rft_id=info:pmid/39684485&rfr_iscdi=true